London, UK, 13 November 2012: MRC Technology, a technology transfer charity and company, announced today Parkinson’s UK is the latest medical research funder to benefit from its recently launched research grant terms approval service. As an expert in commercialising intellectual property, MRC Technology is ideally placed to advise on how best to ensure that grant terms and conditions are comprehensive, meet industry standards, and have the best chance of supporting the development of novel treatments.
Through its review service, MRC Technology performed an overview of Parkinson’s UK’s intellectual property governance and gave its stamp of approval to the charity’s research grant terms and conditions, confirming that they are of the highest standard. This approval is part of an ongoing programme to help Parkinson’s UK maximise the impact of its research.
Organisations that meet the approval criteria display the MRC Technology approval mark.
“We have been approached by both universities and health research charities and were very pleased to be able to offer our services to Parkinson’s UK. Such organisations need to ensure that the results of their funded research are protected and exploited for the advancement of human health. We believe the way to effectively achieve this is by partnering with those that can help – our grant terms approval process facilitates this and promotes positive outcome for patients and researchers,” commented Mike Johnson, Director of Corporate Partnerships, MRC Technology.
Bunia Gorelick, Research Grants Manager. Parkinson’s UK commented, “We value the input MRC Technology has given, and receiving this endorsement from a trusted technology transfer organisation gives Parkinson’s UK confidence that research funded by our organisation will have the greatest impact possible on those affected by the condition in the future.”
MRC Technology plans to continue to expand the new approval service to work with a wide range of medical research charities and organisations, ultimately resulting in more efficient translation of research into real patient benefit.